Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose dexamethasone for embolism syndrome after TACE in primary liver cancer
ChiCTR2100047428Phase 4Recruiting
- Sponsor
- Changhai Hospital
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexamethasone in hepatocellular carcinoma (HCC) and post-embolization syndrome (PES) (2 arms), sponsored by Changhai Hospital. Primary endpoint: Incidence of embolism syndrome. Started Sep 2021; status: recruiting.
02
Drugs
dexamethasone
03
Conditions
hepatocellular carcinoma (HCC)post-embolization syndrome (PES)
Beyond the preview
Go deeper on ChiCTR2100047428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047428.